This article examines the legislative and policy changes to Australia's prescription medicines reimbursement framework and looks at opportunities for companies to maximise outcomes when seeking to list medicines on the government funded Pharmaceutical Benefits Scheme (PBS).

This article is part of the global guide to life sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifesciences-guide.